Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers

BRCA1 and BRCA2 alterations are associated with an increased risk of developing breast carcinoma. The authors hypothesized that the progression of breast neoplasia may differ between patients with hereditary disease and patients with nonhereditary disease and that this difference in progression may be visualized by studying the prevalence of precursor lesions and neoplastic lesions.

[1]  M. Stratton,et al.  Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. , 1998, Journal of the National Cancer Institute.

[2]  P. O’Connell,et al.  Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. , 1998, Journal of the National Cancer Institute.

[3]  C. Bodian,et al.  Prognostic significance of benign proliferative breast disease , 1993, Cancer.

[4]  D. Cosgrove.  The breast , 1999, European Radiology.

[5]  D. Henson,et al.  Benign breast changes and the risk for subsequent breast cancer: an update of the 1985 consensus statement. Cancer Committee of the College of American Pathologists. , 1998, Archives of pathology & laboratory medicine.

[6]  S. Fuqua,et al.  Histological and biological evolution of human premalignant breast disease. , 2001, Endocrine-related cancer.

[7]  A. Ashworth,et al.  The pathology of familial breast cancer: The pathology of familial breast cancer How do the functions of BRCA1 and BRCA2 relate to breast tumour pathology? , 1999, Breast Cancer Research.

[8]  David L. Page,et al.  Diagnostic Histopathology of the Breast , 1988 .

[9]  P. Rosen,et al.  Medullary carcinoma of the breast. A clinicopathologic study with 10 year follow‐up , 1977, Cancer.

[10]  M. Swift,et al.  Breast and other cancers in families with ataxia-telangiectasia. , 1987, The New England journal of medicine.

[11]  M. Skolnick,et al.  Inheritance of proliferative breast disease in breast cancer kindreds. , 1990, Science.

[12]  M. Stanley,et al.  Atypia in breast fine-needle aspiration smears correlates poorly with the presence of a prognostically significant proliferative lesion of ductal epithelium. , 1993, Human pathology.

[13]  S. Cummings,et al.  Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[15]  David L. Page,et al.  Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression , 1995, Nature Genetics.

[16]  T. Sellers,et al.  Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. , 2001, Journal of the National Cancer Institute.

[17]  Y. Miki,et al.  Clinicopathologic analysis of BRCA1‐ or BRCA2‐associated hereditary breast carcinoma in Japanese women , 1999, Cancer.

[18]  F. Melsen,et al.  Prognostic comparison of three classifications for medullary carcinomas of the breast , 1997, Histopathology.

[19]  M. King,et al.  BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. , 2001, Human molecular genetics.

[20]  R. J. Rosser.  Consensus conference on the classification of ductal carcinoma in Situ , 1998, Cancer.

[21]  Thomas Ludwig,et al.  Development of mammary adenocarcinomas by tissue-specific knockout of Brca2 in mice , 2001, Oncogene.

[22]  Dieter Niederacher,et al.  Multistep carcinogenesis of breast cancer and tumour heterogeneity , 1997, Journal of Molecular Medicine.

[23]  G M Lenoir,et al.  Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage , 1996, Cancer.

[24]  I. Andrulis,et al.  HER‐2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry , 2002, Cancer.

[25]  J. Sudbø,et al.  Gene-expression profiles in hereditary breast cancer. , 2001, The New England journal of medicine.

[26]  S J London,et al.  A prospective study of benign breast disease and the risk of breast cancer. , 1992, JAMA.

[27]  J. Feunteun.  Breast cancer and genetic instability: the molecules behind the scenes. , 1998, Molecular medicine today.

[28]  T. Ludwig,et al.  Tumorigenesis in mice carrying a truncating Brca1 mutation. , 2001, Genes & development.

[29]  H M Jensen,et al.  On the origin and progression of ductal carcinoma in the human breast. , 1973, Journal of the National Cancer Institute.

[30]  M. Stratton.  Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases , 1997, The Lancet.

[31]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[32]  D J Schaid,et al.  Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. , 1999, The New England journal of medicine.

[33]  C. Key,et al.  Prevalence of benign, atypical, and malignant breast lesions in populations at different risk for breast cancer. A forensic autopsy study , 1987, Cancer.

[34]  D K Gaffney,et al.  Pathobiologic characteristics of hereditary breast cancer. , 1998, Human pathology.

[35]  R. Kempson,et al.  In situ proliferative epithelial lesions of the breast. , 1992, Pathology.

[36]  J. Tonascia,et al.  Epidemiologic characteristics of benign breast disease. , 1977, American journal of epidemiology.

[37]  T. Sellers,et al.  Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  P. Chappuis,et al.  Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. , 2000, Seminars in surgical oncology.

[39]  M. Greene,et al.  Genetics of breast cancer. , 1997, Mayo Clinic proceedings.

[40]  S. Fosså,et al.  Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumors. , 2001, Journal of the National Cancer Institute.